- Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia
- Myovant, a publicly listed company that is majority-owned by Sumitovant, and its partner Pfizer received FDA acceptance of its supplemental New Drug Application (sNDA) for MYFEMBREE®
- Urovant, a wholly-owned subsidiary of Sumitovant, launched branded co-promotion activities for GEMTESA®
PR Newswire
LONDON and NEW YORK, Dec. 10, 2021